Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ENVB, unsubscribe in one click. Privacy
ENVB holds $8.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.4M/quarter from operations, an estimated runway of 10.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 59 · Elevated
These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ENVB files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENVB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →